Study 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
|
|
- Emerald Nelson
- 5 years ago
- Views:
Transcription
1 Study 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
2 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding the regulatory approval pathway for the bempedoic acid / ezetimibe combination pill and bempedoic acid and the therapeutic potential of, clinical development plan for, the bempedoic acid / ezetimibe combination pill and bempedoic acid, including Esperion's timing, designs, plans and announcement of results regarding its global pivotal Phase 3 clinical development program for bempedoic acid and the bempedoic acid / ezetimibe combination pill, Esperion's timing and plans for submission of NDAs to the FDA and MAAs to the EMA and Esperion's expectations for the market for therapies to lower LDL-C, including the market adoption of bempedoic acid and the bempedoic acid / ezetimibe combination pill, if approved, are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties, including but not limited to, delays or failures in Esperion s studies, that positive results from a clinical study of bempedoic acid may not be sufficient for FDA approval or necessarily be predictive of the results of future or ongoing clinical studies, that existing cash resources may be used more quickly than anticipated, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Esperion disclaims any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. 2 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
3 Bempedoic Acid Franchise Development Program Updates May 2, COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
4 The Lipid Management Team: Addressing a Global Problem Cardiovascular Disease is the #1 Cause of Death Globally Esperion is focused on developing LDL-C lowering therapies to address the unmet needs of patients with atherosclerotic cardiovascular disease (ASCVD), or who are at a high risk for ASCVD, with hypercholesterolemia who continue to have elevated levels of LDL-C despite the use of maximally-tolerated statins and ezetimibe Patients Not Adequately Treated with Currently Available Therapies Phase 3 Study TOTAL STATIN ADD-ON (ASCVD & HeFH) Study 1 & million 8.4 million 4 6 million million ASCVD, HeFH & High Risk for CVD (NO STATIN BACKGROUND) Study 3 & million 3.3 million 0.8 million 7.6 million TOTAL 12.1 million 11.7 million million million Source: AHA Heart Disease, Stroke and Research Statistics At-A-Glance COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
5 Number of Patients in Need of Additional LDL-C Lowering* 12-13M ASCVD and/or HeFH Patients with Elevated LDL-C Bempedoic Acid Franchise Addresses Most Patients Not at LDL-C Treatment Goal 13M 12M 11M 10M 9M 9.5 Million 84% (8M) of these patients will get below 70mg/dL with BA or BA+EZ Patients achieving goals on either BA or BA+EZ Bempedoic acid patients not at goal PCSK9i 8M 7M mg/dl 6M 5M 4M 3M 2M 1M mg/dl 1.8 Million 92% (1.7M) of these patients will get below 100mg/dL with BA or BA+EZ 1.4 Million 14% (200k) of these patients will get below 100mg/dL with BA+EZ Maximally Tolerated Statin Therapy** +/- Ezetimibe Moderate Risk ( mg/dl) High Risk ( mg/dl) Very High Risk (>160 mg/dl) *Excludes Low CVD Risk patients because, by definition, they do not need additional LDL-C lowering **Includes patients only able to tolerate less than the approved daily starting dose of a statin (considered statin intolerant) 5 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
6 Bempedoic Acid and Bempedoic Acid / Ezetimibe Combination Pill to Address Factors Increasingly Critical in LDL-C Treatment Choices Updated treatment goals from ACC/AHA by Q will result in more patients eligible for LDL-C lowering therapy Updated ACC/AHA goals increase demand for complementary, accessible, cost-effective, oral LDL-C lowering therapies to help patients achieve the new treatment goals Payers drawn to cost-effective, convenient, once-daily, oral LDL-C lowering therapies BEMPEDOIC ACID Clinically and Statistically Significant LDL-C Lowering and Reductions in hscrp, Observed to be Safe and Well-Tolerated Targeted Mechanism of Action Complementary and Convenient Oncedaily, Oral Treatment Option Increasing utilization of generic ezetimibe will drive combination pill adoption 6 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
7 Key Upcoming Milestones Results from Three Remaining Phase 3 Studies Expected This Year; NDA Submissions No Later Than Q March Study 4 ( ) BA Ph 3 TLRs August 1002FDC-053 BA / EZ Combo Pill Ph 3 TLRs March 2018 Phase 2 BA PCSK9 Add-on TLRs Q Announce Combination + Statin Future Development Plans 2018 May Study 1 ( ) BA Ph 3 TLRs September Study 2 ( ) BA Ph 3 TLRs Q LDL-C Lowering Indication NDA Submissions Q LDL-C Lowering Indication MAA Submissions 1H 2020 LDL-C Lowering Anticipated Commercial Launch 2022 CLEAR Outcomes CVOT TLRs 2018 Study 3 ( ) BA Ph 3 TLRs Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
8 Bempedoic Acid Phase 3 Program for LDL-C Lowering Pivotal Phase 3 Top-line Results Began Reporting in March LDL-C Lowering Indication (Total N~=4,000): Comparable in Design and Scale to PCSK9i Programs Study 1; Long-Term, N=2,230 TLRs Announced May 2 52 weeks safety / 12 weeks LDL-C ASCVD and/or HeFH Statin Add-On OLE N=1,462 (Fully Enrolled) 1.5 yrs safety Study 2; High Risk, N=779 TLRs Expected in September 12 weeks LDL-C / 52 weeks safety ASCVD and/or HeFH/1 0 ; Low, Very Low or No Statin Background Therapy* Study 3; SI, N=345 TLRs Expected in May Study 4; SI, +EZ, N=269 TLRs announced March 7 12 weeks LDL-C / 12 weeks safety 12 weeks LDL-C / 24 weeks safety ASCVD and/or HeFH/1 0 ; FDC Added to Statin Study 053; N=382 (Fully Enrolled) TLRs Expected in August 12 weeks LDL-C / 12 weeks safety *Studies are being conducted to obtain an indication for use in patients on no background statin therapy in Europe 8 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
9 Clinical Development and Regulatory Strategy Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid Global Clinical Development Programs to Support Target Label(s) Bempedoic Acid / Ezetimibe Combo Pill LDL-C Lowering NDA Submission (No later than Q1 2019) Bempedoic Acid LDL-C Lowering NDA Submission (No later than Q1 2019) CV RR Submission (2022) LDL-C Lowering Program Initial LDL-C Lowering label in U.S. and Europe (like pre-cvot PCSK9i labels in 2015) CLEAR Outcomes CVOT CV Risk Reduction Label in U.S. and Europe (Note: breadth of LDL-C lowering label and CV RR label will broaden similar to post-cvot PCSK9i CV RR label 2017) 9 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
10 Study 1 ( ) Phase 3 Long-Term Safety Study Background Statins and ezetimibe are the standard of care for the treatment of patients with hypercholesterolemia Approximately 90% of patients on LDL-C lowering therapy are taking a low- (12%), moderate- (63%) or high-intensity (25%) statin* The goal of Study 1 was to evaluate the long-term safety and tolerability of bempedoic acid added-on to maximally tolerated statin therapy in high-risk patients with hypercholesterolemia Older, high-risk patients with advanced cardiovascular disease ASCVD and/or HeFH Patients on maximally tolerated statin therapy, including 50% on high-intensity statins and 95% on moderate- or high-intensity statins 52-week study duration the gold standard to evaluate the safety and tolerability of a chronic therapy * Symphony Health Solutions, 2017 Data 10 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
11 Study 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018
12 Study 1 ( ) Long-Term Safety Study Study Design 2230 patients at high CV risk (ASCVD and/or HeFH) with LDL-C 70 mg/dl on stable background lipid-modifying therapy, including maximally tolerated statin therapy Bempedoic acid 180 mg (n=1488) Placebo (n=742) 52-Week Treatment* *Following the 52-week treatment period, patients enrolled in the OLE (N=1,462) or were followed for an additional 30 days for safety (N=768) Primary objective: evaluate the long-term safety and tolerability of bempedoic acid over 52 weeks Overview of adverse events, serious adverse events, discontinuations due to adverse events, fatal adverse events, muscle-related adverse events and safety labs (LFTs) Secondary objective (primary efficacy): change in LDL-C at week COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
13 Study 1 ( ) Long-Term Safety Study Demographics & Baseline Characteristics Mean ± SD a Mean ± SD a Demographics Gender: % Male (M/F) Bempedoic Acid N=1,488 Placebo N=742 Age: years 65.8 ± ± % (1099/389) 71.3% (529/213) Race, White: % (N) 95.6% (1423) 96.5% (716) Ethnicity, Hispanic or Latino: % (N) 1.6% (24) 1.5% (11) Baseline Characteristics BMI: kg/m ± ± 4.9 History of ASCVD Only: % (N) 95.1% (1415) 95.3% (707) HeFH (with or without ASCVD): % (N) 4.9% (73) 4.7% (35) Diabetes: % (N) 28.6% (425) 28.6% (212) Hypertension: % (N) 78.9% (1174) 80.1% (594) LDL-C (mg/dl) Bempedoic Acid N=1,488 Placebo N=742 LDL-C: mg/dl ± ± 30.0 Lipid Parameters and Risk Markers non-hdl-c: mg/dl ± ± 33.9 Total Cholesterol: mg/dl ± ± 35.6 apob: mg/dl 88.5 ± ± 21.8 hscrp: mg/l b HDL-C: mg/dl 48.7 ± ± 11.5 Triglycerides: mg/dl ± ± 64.1 Baseline Statin Intensity % (N) Low 6.7% (100) 6.5% (48) Moderate 43.4% (646) 43.7% (324) High 49.9% (742) 49.9% (370) a Unless otherwise indicated b Median Values Full Analysis Set Population 13 Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
14 Study 1 ( ) Long-Term Safety Study Safety & Tolerability Overview of Adverse Events and Discontinuations Treatment Emergent Adverse Events (AEs) Overview of AEs in All Patients (patient incidence) Bempedoic Acid N=1,487 % (Number) of Patients Placebo N=742 Any AE(s) 78.5% (1167) 78.7% (584) Serious AE(s) 14.5% (216) 14.0% (104) Discontinuation due to AE(s) 10.9% (162) 7.1% (53) Fatal Adverse Events Unrelated to Study Treatment 0.9% (13) 0.3% (2) Safety Analysis Set Population 14 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
15 Study 1 ( ) Long-Term Safety Study Safety & Tolerability Overview of Muscle-Related Adverse Events Note: All patients on background statin therapy with ~95% on moderate- or high-intensity statins Potential Muscle AEs* Overview of Potential Muscle AEs in All Patients (patient incidence) Bempedoic Acid N=1,487 % (Number) of Patients Placebo N=742 Any Potential Muscle AE(s)* 13.1% (195) 10.1% (75) Discontinuation of Study Medication due to Potential Muscle AEs* 2.2% (32) 1.9% (14) All Potential Muscle AEs by MedDRA Preferred Term* Myalgia 6.0% (89) 6.1% (45) Muscle spasms 4.2% (62) 2.7% (20) Pain in extremity 3.4% (50) 2.2% (16) Muscular weakness 0.6% (9) 0.5% (4) Safety Analysis Set Population *Includes all muscular disorders defined in the SAP as: muscle spasms, myalgia, muscular weakness, myoglobin blood increased, myoglobin blood present, myoglobin urine present, myoglobinaemia, myoglobinuria, myopathy, myopathy toxic, necrotizing myositis, pain in extremity, rhabdomyolysis 15 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
16 Bempedoic Acid Integrated Safety LFT Elevations are Rare Overview of Liver Function Tests (AST/ALT) - % (number) of Patients LFT Increases (Repeated and Confirmed) Phase 3 Study 1 (040) Completed Integrated Data 1 Total Ongoing Phase 3 Program 3 Bempedoic Acid N=1,487 Placebo 2 N=742 Bempedoic Acid N=2,434 Placebo 2 N=1,227 Bempedoic Acid N=2,423 Placebo 2 N=1,119 ALT/AST > 3 x ULN 0.54% (8*) 0.13% (1) 0.58% (14*) 0.08% (1) ~0.62% (15*) 0.09% (1) 1 Completed Phase 2/Phase 3 data includes , -005, -006, -007, -008, -009, -014, -035, -038, -039, -048 (Study 4) and -040 (Study 1) 2 Placebo treatment group includes patients with no background therapy; low, moderate, or high intensity statins; and/or ezetimibe; or PCSK9i 3 Based upon blinded data review as of March 2018 for Study 3 and Study 2 subject to variability until the end of the studies and as data are cleaned; assumes all elevations in bempedoic acid-treated patients for Studies 2 and 3; includes final data from Study 1 and Study 4 *Two patients from -040 who rolled over in to the -050 (OLE Study) who reported an initial LFT increase were found not to meet the definition of repeated and confirmed LFT elevations. Incorporating these data, the rate of LFT increases for -040 would be 0.40%; Completed Integrated Data would be 0.49%; Total Ongoing Phase 3 Program would be 0.54%. Overview of Liver Function Tests for Statins and Ezetimibe 4 (AST/ALT) Dose Atorvastatin Rosuvastatin Simvastatin Ezetimibe Vytorin Atorva Placebo Rosuva Placebo Simva Placebo Eze Placebo Vytorin Placebo 10mg 0.2% - 1.1% 0.5% % 0.3% 1.7% - 20mg 0.2% - 1.1% 0.5% - - N/A N/A 1.7% - 40mg 0.6% - 1.1% 0.5% 0.9% - N/A N/A 1.7% - 80mg 2.3% - N/A N/A 2.1% - N/A N/A 2.6% - 4 Data collected from FDA approved package inserts for each drug. Note that all reported Liver Function Test increases occurred within 12 weeks of initiating therapy. 16 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
17 Study 1 ( ) Long-Term Safety Study Safety & Tolerability Overview of Adverse Events Leading to Discontinuation of Study Medication > 1% Incidence Treatment Emergent AEs Overview of AEs in All Patients (patient incidence) % (Number) of Patients Bempedoic Acid N=1,487 Placebo N=742 Discontinuation of Study Medication due to AE(s) 10.9% (162) 7.1% (53) AEs Leading to Discontinuation of Study Medication by System Organ Class Musculoskeletal and connective tissue disorders 2.8% (42) 2.3% (17) Gastrointestinal disorders 1.7% (26) 0.7% (5) Changes in lab values and clinical observations* 1.2% (18) 0.3% (2) Nervous system disorders 1.1% (17) 1.8% (13) *Labeled as Investigations in MedDRA Safety Analysis Set Population 17 Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
18 Study 1 Efficacy
19 Study 1 ( ) Long-Term Safety Study Efficacy Percent Change from Baseline after 12 Weeks 19 Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
20 Study 1 ( ) Long-Term Safety Study Efficacy Percent Change from Baseline after 12 Weeks 20 Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
21 Study 1 Top-Line Data Highlights Bempedoic Acid 180mg Added to Maximally Tolerated Statins (50% on High-Intensity Statins) Observed to be safe and well-tolerated in more than 2,200 high-risk patients with ASCVD and/or HeFH on stable background lipid-modifying therapy, including maximally-tolerated statins Comparable to placebo with similar frequency of AEs, SAEs, muscle-related AEs and discontinuations LFT elevations were low overall and consistent with previous studies Significantly lowered LDL-C by 20% vs. placebo (p<0.001) (on-treatment) Consistent lowering of LDL-C regardless of statin intensity; sustained over time Significantly reduced hscrp by 22% (p<0.001) Significantly lowered non-hdl-c, total cholesterol and apob (p<0.001) 21 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
22 Study 1 ( ) Conclusions Bempedoic Acid Could be an Important New Oral Treatment Option In the largest and longest duration of our Phase 3 studies, bempedoic acid was observed to be safe and well tolerated, and provided clinically and statistically significant LDL-C lowering and reductions in hscrp when added on to maximally tolerated statins (including high-intensity statins). Bempedoic acid could be an important, new, convenient, once-daily, oral treatment option that complements the LDL-C lowering efficacy of available LDL-C lowering therapies, including statins, ezetimibe and PCSK9i. In the coming months, results from three remaining pivotal Phase 3 studies are expected to further validate the efficacy, safety and tolerability profile of bempedoic acid and the bempedoic acid / ezetimibe combination pill as convenient, once-daily, oral therapies that are complementary to existing standard of care LDL-C lowering therapies. 22 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
23 Q & A 23 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE
24 Key Upcoming Milestones Results from Three Remaining Phase 3 Studies Expected This Year; NDA Submissions No Later Than Q March Study 4 ( ) BA Ph 3 TLRs August 1002FDC-053 BA / EZ Combo Pill Ph 3 TLRs March 2018 Phase 2 BA PCSK9 Add-on TLRs Q Announce Combination + Statin Future Development Plans 2018 May Study 1 ( ) BA Ph 3 TLRs September Study 2 ( ) BA Ph 3 TLRs Q LDL-C Lowering Indication NDA Submissions Q LDL-C Lowering Indication MAA Submissions 1H 2020 LDL-C Lowering Anticipated Commercial Launch 2022 CLEAR Outcomes CVOT TLRs 2018 Study 3 ( ) BA Ph 3 TLRs Copyright 2018 Esperion. All Rights Reserved Do Not Copy Or Distribute
Study 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationJMP 2017 Life Sciences Conference. Tim Mayleben
JMP 2017 Life Sciences Conference Tim Mayleben PRESIDENT AND CEO JUNE 21, 2017 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More information34 th Annual JP Morgan Healthcare Conference. January 13, 2016
34 th Annual JP Morgan Healthcare Conference January 13, 2016 SAFE HARBOR Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationBempedoic Acid / Eze.mibe Combina.on Development & Regulatory Update. June 26, 2017
Bempedoic Acid / Eze.mibe Combina.on Development & Regulatory Update June 26, 2017 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentaoon contain forward-looking statements
More informationOppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer
Oppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer New York City 20th March 2019 1 Safe Harbor Forward-looking statements Statements contained in this presentation about
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationEfficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies
Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Michael J. Koren, 1 Evan A. Stein, 2 Eli M. Roth, 3 James M. McKenney, 4 Dan Gipe,
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationEarly Clinical Development #1 REGN727: anti-pcsk9
Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the
More informationMARINE Study Results
TM MARINE Study Results Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements, including those relating to the Company s product development
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationSeladelpar Interim Data Phase 2 Low Dose Study in PBC. July 17, 2017
Seladelpar Interim Data Phase 2 Low Dose Study in PBC July 17, 2017 Seladelpar Phase 2 Low Dose Study in PBC Potential for superior efficacy and better tolerability 39% (5 mg) and 45% (10 mg) reductions
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationNew Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof.
New Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof. Maciej Banach Łódź, PL According to : Central Intelligence Agency". Retrieved
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationDisclosure. This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc.
Disclosure This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc. Effects of 12 Weeks of Treatment with RN316 (PF-04950615), a Humanized
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationResults of ODYSSEY OUTCOMES Trial
Results of ODYSSEY OUTCOMES Trial Evaluation of long-term cardiovascular outcomes after Acute Coronary Syndrome (ACS) during treatment with Praluent (alirocumab) Investor call at ACC, Orlando, March 10,
More informationCompany Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial -- Statistically significantly more patients treated with
More informationPhase 3c Topline Results. Page 1
Phase 3c Topline Results Page 1 Important Information Any statements in this presentation about future expectations, plans and prospects for the Company including the development and regulatory status
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationIR Thematic Call on Alirocumab. March 31 st, 2014
IR Thematic Call on Alirocumab March 31 st, 2014 Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationZafgen PWS Clinical Trial Program Overview. November 16, 2014
Zafgen PWS Clinical Trial Program Overview November 16, 2014 2 Disclaimers Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationChallenges in lipid management
Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationUpdate on inclisiran Discussion of ORION-1 trial
Update on inclisiran Discussion of ORION-1 trial Conference call: March 17, 2017 4:30 pm 5:30 pm, EDT 1 Forward-looking statements Statements contained in this presentation that are not purely historical
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationAcasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C CaPre(R) Met All Primary and Key Secondary Endpoints Statistically
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationRimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, Biohaven
Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, 2018 1 Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationNEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationInvestor Overview. March 2019
Investor Overview March 2019 Forward-Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationPatient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationPatient List Inquiries
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient List Inquiries in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for
More informationPatient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald, PhD Co-authors: Amy Simon 1, Suellen White 1,
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, d Double-blind, bli Placebo- Controlled Study Evan A. Stein 1, David Sullivan 2,
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More information